エピソード

  • Pharmaceutical Executive Daily: Eli Lilly's $1.5 Billion Stockpile of Orforglipron

    Pharmaceutical Executive Daily: Eli Lilly's $1.5 Billion Stockpile of Orforglipron
    2026/02/13
    In today’s Pharmaceutical Executive Daily, Eli Lilly builds a $1.5 billion stockpile of Orforglipron ahead of an FDA decision, PTC Therapeutics withdraws and plans to resubmit its Translarna NDA, and a former AstraZeneca executive is charged with multiple offenses in China.
    続きを読む 一部表示
    1 分
  • Pharmaceutical Executive Daily: FDA Issues Refusal-to-File Letter to Moderna

    Pharmaceutical Executive Daily: FDA Issues Refusal-to-File Letter to Moderna
    2026/02/11
    In today’s Pharmaceutical Executive Daily, the FDA issues a refusal-to-file letter to Moderna for its seasonal influenza vaccine as the company secures a long-term agreement in Mexico, industry leaders assess China’s evolving role in global pharma strategy, and the FDA makes a decision on Keytruda in platinum-resistant ovarian cancer.
    続きを読む 一部表示
    2 分
  • Pharmaceutical Executive Daily: Specialized Wealth Management for BioPharmaceutical Sales

    Pharmaceutical Executive Daily: Specialized Wealth Management for BioPharmaceutical Sales
    2026/02/10
    In today’s Pharmaceutical Executive Daily, frontline biopharma sales professionals are increasingly turning to specialized wealth management advisory services, QuantX Biosciences and Pandorum Technologies close Series B financing rounds, and Iambi enters a $1 billion collaboration with Takeda to advance small-molecule programs.
    続きを読む 一部表示
    2 分
  • Bets and Balances: Riding the Risk-and-Innovation Pendulum in Biotech

    Bets and Balances: Riding the Risk-and-Innovation Pendulum in Biotech
    2026/02/10

    In a podcast conversation with Pharm Exec, Ken Banta, founder and CEO of The Vanguard Network, and Andrew Hall, CEO of Consano Bio, discuss what effective leadership looks like in today’s volatile capital and regulatory climates for emerging biotechs. Part 1 of the conversation explores why Banta and Hall believe CEOs of these companies must act as stabilizers and translators—balancing risk with opportunity and turning complex scientific innovation into clear strategy for investors, regulators, and employees alike.

    Highlights of the discussion include:

    • The EQ imperative: leading through persuasion and influence, not dictates. “It’s not about the science; it’s about the people.”
    • The best CEOs follow a four-core formula
    • Early stage’s mindset mix (end-game vs journey)—and the rewards of “failing fast”
    • Why Series A’s are the “lifeblood of biotech”
    続きを読む 一部表示
    18 分
  • Pharmaceutical Executive Daily: Hims & Hers Removes Access to New Compounded Semaglutide Pill

    Pharmaceutical Executive Daily: Hims & Hers Removes Access to New Compounded Semaglutide Pill
    2026/02/09
    In today’s Pharmaceutical Executive Daily, Hims & Hers withdraws access to its compounded semaglutide pill following a controversy filled launch, next-generation trial designs increasingly integrate real-world data, and Eli Lilly enters an $8 billion strategic collaboration involving Innovent and Orna Therapeutics.
    続きを読む 一部表示
    2 分
  • Pharmaceutical Executive Daily: The Launch of TrumpRx

    Pharmaceutical Executive Daily: The Launch of TrumpRx
    2026/02/06
    In today’s Pharmaceutical Executive Daily, TrumpRx officially launches, the FDA moves against mass marketing of illegal copycat drugs, and AI emerges as a force multiplier for small and mid-size biotech companies
    続きを読む 一部表示
    2 分
  • Pharmaceutical Executive Daily: FDA Approves First and Only Oral Film Treatment for Erectile Dysfunction

    Pharmaceutical Executive Daily: FDA Approves First and Only Oral Film Treatment for Erectile Dysfunction
    2026/02/05
    In today’s Pharmaceutical Executive Daily, FDA approves Vybrique for erectile dysfunction, experts argue Phase III clinical protocols should be treated as product launch blueprints, and Veradermics completes an upsized $256 million IPO.
    続きを読む 一部表示
    2 分
  • Pharmaceutical Executive Daily: Susan G. Komen Releases Breast Cancer Outlook for 2026

    Pharmaceutical Executive Daily: Susan G. Komen Releases Breast Cancer Outlook for 2026
    2026/02/04
    In today’s Pharmaceutical Executive Daily, Susan G. Komen releases its 2026 breast cancer progress outlook, industry leaders explore how pharma can tap into emerging talent hubs, and Novartis’ Q4 results highlight mounting pressure from its upcoming patent cliff.
    続きを読む 一部表示
    2 分